$412.82
3.15% today
Nasdaq, Apr 03, 06:44 pm CET
ISIN
US45168D1046
Symbol
IDXX
Sector

IDEXX Laboratories Stock price

$426.25
-10.90 2.49% 1M
-59.72 12.29% 6M
+12.81 3.10% YTD
-95.42 18.29% 1Y
-121.83 22.23% 3Y
+186.55 77.83% 5Y
+349.71 456.90% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+7.68 1.83%
ISIN
US45168D1046
Symbol
IDXX
Sector

Key metrics

Market capitalization $34.54b
Enterprise Value $35.24b
P/E (TTM) P/E ratio 39.96
EV/FCF (TTM) EV/FCF 43.61
EV/Sales (TTM) EV/Sales 9.04
P/S ratio (TTM) P/S ratio 8.86
P/B ratio (TTM) P/B ratio 21.80
Revenue growth (TTM) Revenue growth 6.46%
Revenue (TTM) Revenue $3.90b
EBIT (operating result TTM) EBIT $1.13b
Free Cash Flow (TTM) Free Cash Flow $808.08m
Cash position $288.27m
EPS (TTM) EPS $10.67
P/E forward 35.59
P/S forward 8.39
EV/Sales forward 8.56
Short interest 4.79%
Show more

Create a Free Account to create an IDEXX Laboratories alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

IDEXX Laboratories Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a IDEXX Laboratories forecast:

8x Buy
57%
6x Hold
43%

Analyst Opinions

14 Analysts have issued a IDEXX Laboratories forecast:

Buy
57%
Hold
43%

Financial data from IDEXX Laboratories

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
3,898 3,898
6% 6%
100%
- Direct Costs 1,519 1,519
3% 3%
39%
2,378 2,378
9% 9%
61%
- Selling and Administrative Expenses 901 901
14% 14%
23%
- Research and Development Expense 220 220
15% 15%
6%
1,257 1,257
4% 4%
32%
- Depreciation and Amortization 130 130
13% 13%
3%
EBIT (Operating Income) EBIT 1,127 1,127
3% 3%
29%
Net Profit 888 888
5% 5%
23%

In millions USD.

Don't miss a Thing! We will send you all news about IDEXX Laboratories directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IDEXX Laboratories Stock News

Positive
The Motley Fool
5 days ago
Healthcare diagnostics equipment manufacturer, Idexx Laboratories (IDXX -1.54%), is the global leader in pet care.
Positive
Seeking Alpha
17 days ago
Upgraded IDEXX to 'Buy' with a $450 price target due to oncology business expansion and share repurchase program. IDEXX's oncology market entry with Cancer Dx panel in March 2025 could drive significant growth and new revenue streams. IDEXX's share repurchase program is robust, with $837 million repurchased in FY24 and a plan for $1.5 billion in FY25.
Positive
Seeking Alpha
22 days ago
The pet care industry is growing, with increasing pet ownership and spending, especially in emerging markets, providing IDEXX with significant growth opportunities. IDEXX Laboratories is the market leader with a highly profitable business model, operating leverage, and recurring revenues. Once a customer starts using an IDEXX instrument, it is tied to the IDEXX ecosystem.
More IDEXX Laboratories News

Company Profile

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: CAG, Water, LPD, and Other. The CAG segment develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management. The Water segment develops, designs, manufactures, and distributes a range of products used in the detection of various microbiological parameters in water. The LPD segment develops, designs, manufactures, and distributes diagnostic tests and related instrumentation and performs services, which are used to manage the health status of livestock and poultry, to improve producer, and to ensure the quality and safety of milk and food. The Other operating segment combines and presents products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983 and is headquartered in Westbrook, ME.

Head office United States
CEO Jonathan Mazelsky
Employees 11,000
Founded 1983
Website www.idexx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today